NCT02560610View on ClinicalTrials.gov

Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma

PHASE2CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

August 2, 2018

Study Completion Date

August 2, 2018

Conditions

Severe Eosinophilic Asthma

Interventions

DRUG

OC000459

DRUG

Placebo

Trial Locations (1)

Unknown

University of Oxford, Oxford

Sponsors

Collaborators (1)

Atopix Therapeutics, Ltd.

All Listed Sponsors

collaborator

Atopix Therapeutics, Ltd.

INDUSTRY

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02560610 - Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma | Biotech Hunter | Biotech Hunter